Eur J Endocrinol
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

European Journal of Endocrinology, Vol 131, Issue 2, 125-130
Copyright © 1994 by European Society of Endocrinology
This Article
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kuo, S.
Right arrow Articles by Wu, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kuo, S.
Right arrow Articles by Wu, S.
Articles

Effect of thyroxine administration on serum thyrotropin receptor antibody and thyroglobulin levels in patients with Graves' hyperthyroidism during antithyroid drug therapy

SW Kuo, WS Huang, CA Hu, WK Liao, TC Fung, and SY Wu

Thyroid Laboratory, Tri-Service General Hospital, Taipei, Taiwan, ROC.

Graves' hyperthyroidism is due primarily to overproduction of antibodies to thyrotropin receptors (TR-ab), which stimulate the thyroid gland and cause hyperthyroidism. Antibody production during antithyroid drug therapy is an important determinant of the course of the disease. We therefore observed the changes of serum TR-ab, thyroglobulin (Tg) and thyroid hormone levels in response to administration of L-thyroxine (T4) in Graves' hyperthyroid patients during antithyroid drug therapy. Serum levels of TR-ab, Tg and other thyroid hormones were measured by radioimmunoassay (RIA) during either methimazole treatment alone or in combination with thyroxine in 60 Graves' hyperthyroid patients. The patients initially were treated with 30 mg of methimozole daily for 3 months, which was then reduced to 15 mg daily for the following 3 months. All patients were euthyroid 6 months after the start of antithyroid therapy and the TR-ab level decreased from 61 +/- 11% (+/- SD) to 28 +/- 7% (p < 0.01). Patients then were divided into three groups: group A (N = 25), whose TR-ab level was 10% or more (the cut-off value for positivity), received 0.1 mg of T4 and 10 mg of methimazole daily for 6 months; group B (N = 15), whose TR-ab level also was 10% or more and was age- and thyroid function-matched with group A, received only 10 mg of methimazole daily for 6 months; group C (N = 20), with a TR-ab level of less than 10%, received 10 mg of methimazole alone daily for 6 months.(ABSTRACT TRUNCATED AT 250 WORDS)


This article has been cited by other articles:


Home page
 Proc. Natl. Acad. Sci. USAHome page
S. Lisi, A. Pinchera, R. T. McCluskey, T. E. Willnow, S. Refetoff, C. Marcocci, P. Vitti, F. Menconi, L. Grasso, F. Luchetti, et al.
Preferential megalin-mediated transcytosis of low-hormonogenic thyroglobulin: A control mechanism for thyroid hormone release
PNAS, December 9, 2003; 100(25): 14858 - 14863.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
R. S. Rittmaster, E. C. Abbott, R. Douglas, M. L. Givner, L. Lehmann, S. Reddy, S. R. Salisbury, A. H. Shlossberg, M. H. Tan, and S. E. York
Effect of Methimazole, with or without L-Thyroxine, on Remission Rates in Graves' Disease
J. Clin. Endocrinol. Metab., March 1, 1998; 83(3): 814 - 818.
[Abstract] [Full Text]

Home page
 J. Clin. Endocrinol. Metab.Home page
A. Lucas, I. Salinas, F. Rius, E. Pizarro, M.L. Granada, M. Foz, and A. SanmartI
Medical Therapy of Graves' Disease: Does Thyroxine Prevent Recurrence of Hyperthyroidism?
J. Clin. Endocrinol. Metab., August 1, 1997; 82(8): 2410 - 2413.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1994 European Society of Endocrinology.